Dabrafenib + Trametinib in Patients w/rare BRAF V600E Mutated Solid Tumor (CDRB436IIC01)

What is the Purpose of this Study?

We are doing this study to collect information about how well dabrafenib plus trametinib works in patients who have unresectable (cannot be removed by surgery) or metastatic BRAF V600E mutation positive solid tumors.

What is the Condition Being Studied?

Unresectable or Metastatic BRAF V600E Mutation Positive Solid Tumors

Who Can Participate in the Study?

Adults ages 18+ who:

  • Are diagnosed with unresectable or metastatic BRAF V600E mutation positive solid tumors
  • Have not received dabrafenib-trametinib previously for your disease or have not received it for more than one year for any other malignancy

For more information about who can join this study, please contact the study team at gi-oncology-cru@dm.duke.edu or 919-668-1861.

Age Group

What is Involved?

If you choose to join this study, we will collect information related to your cancer and treatment and enter it into a database that we will keep indefinitely. This information will help us better understand how the drug combination works for people who have this rare mutation.

Study Details

Full Title
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
Principal Investigator
Professor of Medicine
Protocol Number
IRB: PRO00113811
NCT: NCT05868629
Phase IV
Enrollment Status